SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lipocine, Inc. - LPCN

NEW YORK, June 29, 2016

[Click here to join a class action]

The investigation concerns whether Lipocine and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On June 29, 2016, pre-market, the Company announced that the FDA issued a Complete Response Letter ("CRL") regarding its New Drug Application for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.  The CRL identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.  Specifically, the proposed titration scheme for clinical practice was significantly different from the titration scheme used in the Phase 3 trial leading to discordance in titration decisions between the Phase 3 trial and real-world clinical practice. 

On this news, Lipocine stock fell as much as $3.67 per share or 58.61%, during intraday trading on June 29, 2016. 

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com